Objective:

To summarize the key clinical updates on kidney cancer presented at ESMO 2024.

Key Findings:

• No benefit from adding nivolumab to Tavo nib after prior immunotherapy in RCC.
• It be evil shows promise in non-clear cell RCC with a 12-month OS benefit.
• Combination of Alat NIB and anti-PD-L1 shows PFS improvement but lacks OS significance.

Interpretation:

The findings suggest limited efficacy of combining immunotherapy with TKI in patients who have progressed on prior immunotherapy, while novel treatments like it be evil may offer new options for non-clear cell RCC.

Limitations:

• The studies primarily focus on specific patient populations, limiting generalizability.
• Some trials did not reach maturity for overall survival data.

Conclusion:

Emerging therapies and combinations in RCC show varying degrees of efficacy, with some promising results in specific subtypes, warranting further investigation.